BCM
PTGX icon

BlueCrest Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

BlueCrest Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-21,380
Closed -$269K – 898
2019
Q1 		$269K Buy
21,380
+7,092
+50% +$62.6K 0.01% 771
2018
Q4 		$96K Sell
14,288
-5,213
-27% -$41.3K ﹤0.01% 767
2018
Q3 		$201K Sell
19,501
-47,778
-71% -$411K 0.01% 1272
2018
Q2 		$452K Buy
+67,279
New +$516K 0.01% 893

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

BlueCrest Capital Management's PTGX Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Protagonist Therapeutics (PTGX) in Q2 2019, closing a stake of 21,380 shares — an estimated $269K sold.

BlueCrest Capital Management first reported a position in PTGX in Q2 2018 and held it in 4 quarters. The position peaked at $452K in Q2 2018. 66 funds tracked by Wall St. Rank hold PTGX as of Q2 2019.

  • BlueCrest Capital Management reported no remaining Protagonist Therapeutics position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 21,380 Protagonist Therapeutics shares in Q2 2019, an estimated $269K.
  • BlueCrest Capital Management first reported a position in Protagonist Therapeutics in Q2 2018 and held it in 4 quarters.
  • BlueCrest Capital Management's Protagonist Therapeutics position peaked at $452K in Q2 2018.
  • 66 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.